Thanks for posting MAL85,
Venetoclax is certainly a promising looking treatment but it does appear to be in early stage of trials and to date appears to only have been trialed for “patients with Chronic Lymphocytic Leukaemia (CLL) and AIM Study in Mantle-Cell Lymphoma (MCL)” and not for patients with AML. So if Venetoclax does prove to be a winner for CLL and MCL it may be a while before it moves through trials and is eventually approved for CLL and MCL - and then how long before it enters phase 1 trials for AML? Assuming it does enter phase 1 trials for AML and is eventually successful after phase 1, 2 and 3 trials, it may be a long time before it hits the market for AML leaving the door open for others that are already moving into phase 3 trials and likely to get to market much earlier.
Also worth keeping in mind that in the shorter term RAC could receive its Priority Review Voucher worth around $100mill US or around A$140-145mill. That possibility certainly does not seem to be currently factored into the RAC sp.
RAC Price at posting:
13.5¢ Sentiment: Buy Disclosure: Held
(20min delay)